Payment overview · 2025
General Payments
$1,524.52
14 reported records · 12 companies
Healthcare provider profile · identity verified
Charlene Walton Windham
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Gerontology · SOUTHFIELD, MI · NPI 1518336080
Verified facts
What the public records show
CMS Open Payments records show Charlene Walton Windham received $1,524.52 in general payments during 2025 across 14 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $238.67 | 15.7% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$131.91 | 8.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $126.31 | 8.3% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $126.00 | 8.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $125.00 | 8.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $124.99 | 8.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $124.74 | 8.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $121.83 | 8.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $113.40 | 7.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $107.10 | 7.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $93.70 | 6.2% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $90.87 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,524.52 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $238.67 | 3 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $131.91 | 1 | 2025 |
Source payment records
|
|||||
| CERDELGA Normalized: cerdelga |
Drug | GENZYME CORPORATION | $126.31 | 1 | 2025 |
Source payment records
|
|||||
| CEREZYME Normalized: cerezyme |
Biological | GENZYME CORPORATION | $126.31 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $113.40 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $107.10 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $93.70 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $90.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
153 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 571 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 353 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 264 | 39 |
| Furosemide | Furosemide | 231 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 37 |
| Gabapentin | Gabapentin | 226 | 31 |
| Losartan Potassium | Losartan Potassium | 207 | 33 |
| Omeprazole | Omeprazole | 185 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 179 | 19 |
| Lisinopril | Lisinopril | 179 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 25 |
| Eliquis | Apixaban | 153 | 26 |
| Metformin Hcl | Metformin Hcl | 147 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 21 |
| Sertraline Hcl | Sertraline Hcl | 135 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 23 |
| Latanoprost | Latanoprost | 122 | 20 |
| Potassium Chloride | Potassium Chloride | 122 | 21 |
| Memantine Hcl | Memantine Hcl | 100 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 12 |
| Trazodone Hcl | Trazodone Hcl | 98 | 13 |
| Mirtazapine | Mirtazapine | 93 | suppressed |
| Carvedilol | Carvedilol | 92 | 12 |
| Donepezil Hcl | Donepezil Hcl | 92 | 15 |
| Famotidine | Famotidine | 80 | 15 |
| Xarelto | Rivaroxaban | 76 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 75 | 19 |
| Buspirone Hcl | Buspirone Hcl | 73 | 12 |
| Jardiance | Empagliflozin | 73 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 65 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | suppressed |
| Pregabalin | Pregabalin | 64 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 61 | suppressed |
| Ezetimibe | Ezetimibe | 60 | suppressed |
| Olanzapine | Olanzapine | 59 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 58 | suppressed |
| Allopurinol | Allopurinol | 57 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 54 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 49 | suppressed |
| Baclofen | Baclofen | 48 | suppressed |
| Spironolactone | Spironolactone | 47 | suppressed |
| Alprazolam | Alprazolam | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Simvastatin | Simvastatin | 40 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Risperidone | Risperidone | 39 | suppressed |
| Adlarity | Donepezil Hcl | 38 | suppressed |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Klor-Con M20 | Potassium Chloride | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 34 | 11 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Prednisone | Prednisone | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Xifaxan | Rifaximin | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Bimatoprost | Bimatoprost | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fetzima | Levomilnacipran Hcl | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,524.52 · 14 records | E.R. Squibb & Sons, L.L.C. | BENLYSTA, BRIXADI, CAPLYTA, CERDELGA, CEREZYME, COBENFY, Leqembi, SYMPLICITY G3, UBRELVY, UZEDY, WAINUA, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error